GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT04176939
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Linerixibat Long-term Safety, and Tolerability Study
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 305
- Registration Number
- NCT04167358
- Locations
- 🇬🇧
GSK Investigational Site, Surrey, United Kingdom
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 325
- Registration Number
- NCT04162210
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT04151225
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT04138043
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 509
- Registration Number
- NCT04138056
- Locations
- 🇨🇦
GSK Investigational Site, London, Ontario, Canada
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT04136145
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 550
- Registration Number
- NCT04134728
- Locations
- 🇬🇧
GSK Investigational Site, Northwood, Middlesex, United Kingdom
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 806
- Registration Number
- NCT04133909
- Locations
- 🇬🇧
GSK Investigational Site, Wishaw, United Kingdom
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 315
- Registration Number
- NCT04128696
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom